Inactive/Delisted stock

Scilex Stock (NASDAQ:SCLX)


Chart

Previous Close

$6.47

52W Range

$3.60 - $80.50

50D Avg

$5.93

200D Avg

$18.62

Market Cap

$43.86M

Avg Vol (3M)

$120.96K

Beta

1.14

Div Yield

-

SCLX Company Profile


Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

115

IPO Date

Mar 05, 2021

Website

SCLX Performance


Peer Comparison


TickerCompany
SNYSanofi
GSKGSK plc
ABBVAbbVie Inc.
NVSNovartis AG
AZNAstraZeneca PLC
MRKMerck & Co., Inc.
GILDGilead Sciences, Inc.
BMYBristol-Myers Squibb Company
BIIBBiogen Inc.
AMGNAmgen Inc.
LLYEli Lilly and Company